Solid Biosciences (SLDB) Receivables (2021)
Solid Biosciences (SLDB) posted Receivables of $220000.0 for Q4 2021.
Powered by 
Analysis
Solid Biosciences (SLDB) Receivables (2021) Analysis & Trends
Solid Biosciences has reported Receivables for 1 years, with the latest figure at $220000.0 in Q4 2021.
- Quarterly Receivables changed N/A year-over-year to $220000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $220000.0 (changed N/A YoY) and the FY2021 annual result came in at $220000.0, changed N/A from the prior year.
- Receivables was little changed at $220000.0 in Q4 2021 per SLDB's latest filing.
- Over five years, Receivables peaked at $220000.0 in Q4 2021 and troughed at $220000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Solid Biosciences | 1.48 Bn | 1.48 Bn | - | - |